Skip to content

Smith & Nephew

US · SNN #1382 by market cap Listed 1970
26.89 +0.02 +0.07%
Live - 5344 symbols - heartbeat 323s ago · 2026-10-08 07:36
Pre-market 26.43 -1.71%
After-hours 26.89 0.00%
Market cap
11.25B
P/B
2.17
EPS
1.43
Reader sentiment Are you bullish or bearish on SNN?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Below fair value
32.16 fair value ≈ 49.89 67.62
  • Implied fair-value range of 32.16-67.62, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -46.1% below the average-multiple fair value of 49.89.

Valuation each multiple against its own 5-year range

P/B ratio 2.18 Cheap vs history 26th percentile
5-year average 2.39 · #53 of 125 in Medical Devices
P/E ratio 18.33 Cheap vs history 1st percentile
5-year average 34.84 · forward 15.23 · #9 of 38 in Medical Devices
P/S ratio 1.79 Cheap vs history 1st percentile
5-year average 2.30 · forward 1.70 · #48 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Smith & Nephew (SNN) 11.25B 18.29 2.17 2.91%
Abbott Laboratories (ABT) 170.84B 31.95 3.34 2.47%
Medtronic (MDT) 109.38B 21.06 2.18 3.33%
Stryker Corp (SYK) 105.64B 28.54 4.40 1.26%
Boston Scientific (BSX) 60.26B 16.83 2.42 0.00%
Edwards Lifesciences (EW) 49.44B 49.87 4.66 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value35.52 Economic moatNarrow UncertaintyLow

Trading 32.1% below Morningstar's fair value estimate.

Fair value

Smith & Nephew PLC receives a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 24% discount to our quantitative fair value estimate of $35.52 per share, which is reinforced by this estimate's low uncertainty rating.

The company's valuation metrics bolster our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio of 6.5 lies in the bottom 20% compared with peers globally. Relative to the company's EBITDA, the enterprise value of the business is low, which contributes to our view that shares are cheap.

The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 8.0%, for example, falls in the top 30% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.

Economic moat

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-08 07:36:10 · For reference only, not investment advice and not tailored to your situation.